濮阳东方看男科口碑非常好濮阳东方妇科口碑,濮阳东方妇科医院做人流口碑非常好,濮阳东方妇科医院口碑好收费低,濮阳东方医院男科治早泄评价好很专业,濮阳东方医院男科治早泄技术专业,濮阳市东方医院好么,濮阳东方男科医院价格不高

BEIJING, Feb. 11 (Xinhua) -- China's foreign exchange regulator said Friday it did not suffer any losses from its investment in Fannie Mae and Freddie Mac bonds, adding that media reports of up to 450 billion U.S. dollars of losses were "groundless.""Up until now, the capital and interest repayments of Fannie Mae and Freddie Mac bonds is normal, and no losses have incurred," The State Administration of Foreign Exchange (SAFE) said on its website.Annual yields of the bonds were around 6 percent between 2008 and 2010, the SAFE said.The regulator, which oversees China's more than 2 trillion U.S. dollars of foreign exchange reserve, also clarifies it had not bought any stocks of the two troubled mortgage companies.UPI reported on Friday that the Obama Administration will propose phasing out the two mortgage giants after rescuing them, which is part of a U.S. Treasury Department white paper to Congress that lays out three ways of cutting government support to the 10.6 trillion U.S. dollars mortgage market.

HARBIN, March 2 (Xinhua) -- A therapeutic apparatus to treat Parkinson's disease has been developed in northeast China's Heilongjiang Province, according to the provincial science and technology department. It is a worldwide breakthrough in treating the disease with transcranial magnetic stimulation, concluded an expert panel with the Heilongjiang Provincial Department of Science and Technology.The team said it came to the conclusion after evaluating technical documents and clinical test results Monday.This is the first time that transcranial magnetic stimulation has been adopted to treat Parkinson's disease, said Sun Zuodong, chairman of Aobo Medicine Apparatus Co., Ltd. (AMA), the developer based in the provincial capital Harbin.Transcranial magnetic stimulation is a noninvasive method which causes depolarization in the brains' neurons so as to restore the functions of brain nerves.The apparatus consists of three parts, namely brain wave stimulator, field effect cap and multiplier, said Sun.Clinical tests over more than 100 patients showed that the apparatus had a 70 percent success rate in reducing the disease's symptoms, according to Wang Aili, planning manager of AMA.The new equipment will help generation of dopamine, the reduction of which within the brain caused the disease, said Wang Weixiang, a consulting doctor with the Heilongjiang Provincial Rehabilitation Hospital.Parkinson's disease is a disorder of the neural system, which leads to limb tremors and difficulty in walking and other movements.China has 2 million patients suffering from Parkinson's disease, mostly people over the age of 50, and the number is increasing by 100,000 annually, said Dr. Wang.

WASHINGTON, April 11 (Xinhua) -- Taking a statin before having major elective surgery reduces potentially serious kidney complications, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology.Each year, more than 230 million major elective surgeries are performed around the world. Unfortunately, many patients who undergo major operations develop kidney injury soon after surgery, often due to decreased blood flow to the kidneys and/or the effects of inflammation.Animal studies suggest that the cholesterol-lowering drugs called statins protect the kidneys from such damage, but whether a similar benefit occurs in humans is uncertain. To investigate, Amber Molnar, University of Western Ontario, and colleagues conducted a population-based retrospective study of all older patients who underwent major elective surgery in the province of Ontario, Canada from 1995 to 2008. Surgeries included cardiac, thoracic, vascular, intra-abdominal, and retroperitoneal procedures.A total of 213,347 patients from 211 hospitals underwent major elective surgery, and 4,020 patients (1.9 percent) developed postoperative kidney injury within two weeks of surgery. A total of 1,173 patients (0.5 percent) required dialysis within two weeks of surgery, and 5,974 patients (2.8 percent) died within a month of surgery.Prior to surgery, 67,941 patients (32 percent) were taking a statin. Patients taking a statin were 20 percent less likely to develop kidney injury, need dialysis, and die compared to patients who were not taking a statin. Also, there was evidence of a dose-effect, with patients on higher potency statins having less kidney injury. In addition, statins were beneficial whether they were started greater than 90 days or less than 30 days prior to surgery."Our study suggests that statin use in older persons results in less kidney injury following major elective surgery and reduces the risk of premature death after surgery," said Molnar, adding that the results warrant further investigation with more rigorous studies, but such trials will be difficult to carry out.

WASHINGTON, May 20 (Xinhua) -- The U.S. Food and Drug Administration (FDA) on Friday approved Sutent to treat patients with progressive neuroendocrine cancerous tumors located in the pancreas that cannot be removed by surgery or that have spread to other parts of the body.Neuroendocrine tumors found in the pancreas are slow-growing and rare. It is estimated that there are fewer than 1,000 new cases in the United States each year.This is the second new approval by the FDA to treat patients with this disease. On May 5, the agency approved Afinitor."FDA believes it is important to provide cancer patients with as many treatment options as possible," said Richard Pazdur, director of the Office of Oncology Drug Products in the FDA's Center for Drug Evaluation and Research. "The agency is committed to working with companies to bring innovative new therapies to the market and encourages companies to continue exploring additional uses for approved products."The safety and effectiveness of Sutent was established in a single study of 171 patients with metastatic (late-stage) or locally advanced (disease that could not be removed with surgery) disease who received Sutent or a placebo (sugar pill). The study was designed to measure the length of time a patient lived before their disease spread or worsened (progression-free survival).Results from the study demonstrate that Sutent provided benefit to patients by prolonging the median length of time they lived without the cancer spreading or worsening to 10.2 months compared to 5.4 months for patients who received placebo.In patients treated with Sutent for neuroendocrine pancreatic tumors, the most commonly reported side effects included diarrhea, nausea, vomiting, fatigue, anorexia, high blood pressure, energy loss, stomach pain, changes in hair color, inflammation of the mouth, and a decrease in infection-fighting white blood cells.Sutent is marketed by New York City-based Pfizer.

BEIJING, Feb. 26 (Xinhua) -- China's Ministry of Education said Friday that 34.29 million students graduated from the country's higher-learning institutions between 2006 and 2010.Xu Mei, the ministry's spokeswoman, said the number is even more than that of the graduates in the 20 years prior to 2006 combined."During the 11th five-year plan period (2006-2010), higher education has become even more accessible to the general public. Higher-learning institutions provide a strong support of brain power and human resources to the social and economic development," Xu said.The "Outline of China's National Plan for Medium and Long-Term Education Reform and Development (2010-2020)," which was publicized last year, says "the strategic goals to be attained by 2020 are to basically modernize education; shape a learning society; and turn China into a country rich in human resources."